A multimorphic variant in ThPOK causes an inborn error of immunity with T cell defects and fibrosis
- PMID: 40392549
- PMCID: PMC12091070
- DOI: 10.1084/jem.20241174
A multimorphic variant in ThPOK causes an inborn error of immunity with T cell defects and fibrosis
Abstract
ThPOK is a transcription factor that acts as a master regulator of CD4+ T cell lineage commitment. We report the first human disease caused by a genetic alteration in ThPOK, specifically, a damaging heterozygous de novo variant in ThPOK (NM_001256455.2:c.1080A>C, p.K360N). This patient exhibited the unusual constellation of persistent CD4+ T cell deficiency, allergy, interstitial lung disease, corneal vascularization and scarring, developmental delay, and growth failure. The ThPOKK360N variant displayed abnormal multimorphic activity, interfering with ThPOKWT (antimorph), failing to bind wild-type ThPOK consensus sequences (amorph), and showing novel DNA-binding specificity (neomorph). Single-cell RNA sequencing revealed defects in CD4+ and CD8+ T cell maturation and activation (hypomorph). Recapitulated in lentivirally transduced healthy control T cells and fibroblasts, the transcriptomic analysis showed ThPOKK360N-transduced T cells had impaired TCR activation and ThPOKK360N-transduced fibroblasts with increased profibrotic gene expression. This novel human disease confirms ThPOK's role in CD4+ T cell development but also uncovers novel roles in TCR activation and regulation of fibrotic pathways in fibroblasts.
© 2025 Vaseghi-Shanjani et al.
Conflict of interest statement
Disclosures: J.H. Rayment reported personal fees from Vertex Pharmaceuticals, personal fees from Boehringer Ingelheim, and grants from Vertex Pharmaceuticals outside the submitted work. No other disclosures were reported.
References
-
- Carpenter, A.C., Grainger J.R., Xiong Y., Kanno Y., Chu H.H., Wang L., Naik S., dos Santos L., Wei L., Jenkins M.K., et al. 2012. The transcription factors Thpok and LRF are necessary and partly redundant for T helper cell differentiation. Immunity. 37:622–633. 10.1016/j.immuni.2012.06.019 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
